Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kengo Azushima

Showing results (71-80 of 109) with videos related to

Pageof 11
Sort By:
Clinical and Experimental Hypertension (New York, N.Y. : 1993)|May 11, 2012
Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY)Akinobu Maeda, Kouichi Tamura, Tomohiko Kanaoka, et al.
Journal of the American Heart Association|August 2, 2013
Angiotensin receptor-binding protein ATRAP/Agtrap inhibits metabolic dysfunction with visceral obesityAkinobu Maeda, Kouichi Tamura, Hiromichi Wakui, et al.
Kidney Diseases (Basel, Switzerland)|September 9, 2020
Effects of Erythropoietin-Stimulating Agents on Blood Pressure in Patients with Non-Dialysis CKD and Renal AnemiaKohji Ohki, Hiromichi Wakui, Kazushi Uneda, et al.
International Journal of Molecular Sciences|November 27, 2021
Aristolochic Acid Induces Renal Fibrosis and Senescence in MiceShingo Urate, Hiromichi Wakui, Kengo Azushima, et al.
Clinical and Experimental Hypertension (New York, N.Y. : 1993)|May 15, 2012
Relationship of ambulatory blood pressure and the heart rate profile with renal function parameters in hypertensive patients with chronic kidney diseaseTomohiko Kanaoka, Kouichi Tamura, Masato Ohsawa, et al.
Biomed Research International|December 6, 2018
Early Enhanced Leucine-Rich <i>α</i>-2-Glycoprotein-1 Expression in Glomerular Endothelial Cells of Type 2 Diabetic Nephropathy Model MiceSona Haku, Hiromichi Wakui, Kengo Azushima, et al.
Cardiovascular Diabetology|January 8, 2021
Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysisTakayuki Yamada, Mako Wakabayashi, Abhinav Bhalla, et al.
Metabolism: Clinical and Experimental|October 19, 2023
Angiotensin II type 1 receptor-associated protein in immune cells: a possible key factor in the pathogenesis of visceral obesityShunichiro Tsukamoto, Toru Suzuki, Hiromichi Wakui, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|April 5, 2013
Therapeutic potential of low-density lipoprotein apheresis in the management of peripheral artery disease in patients with chronic kidney diseaseKouichi Tamura, Yuko Tsurumi-Ikeya, Hiromichi Wakui, et al.
Scientific Reports|August 20, 2021
Tissue-specific expression of the SARS-CoV-2 receptor, angiotensin-converting enzyme 2, in mouse models of chronic kidney diseaseShunichiro Tsukamoto, Hiromichi Wakui, Kengo Azushima, et al.
Pageof 11

Showing results (71-80 of 109) with videos related to

Sort By:
Pageof 11
Clinical and Experimental Hypertension (New York, N.Y. : 1993)|May 11, 2012
Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY)Akinobu Maeda, Kouichi Tamura, Tomohiko Kanaoka, et al.
Journal of the American Heart Association|August 2, 2013
Angiotensin receptor-binding protein ATRAP/Agtrap inhibits metabolic dysfunction with visceral obesityAkinobu Maeda, Kouichi Tamura, Hiromichi Wakui, et al.
Kidney Diseases (Basel, Switzerland)|September 9, 2020
Effects of Erythropoietin-Stimulating Agents on Blood Pressure in Patients with Non-Dialysis CKD and Renal AnemiaKohji Ohki, Hiromichi Wakui, Kazushi Uneda, et al.
International Journal of Molecular Sciences|November 27, 2021
Aristolochic Acid Induces Renal Fibrosis and Senescence in MiceShingo Urate, Hiromichi Wakui, Kengo Azushima, et al.
Clinical and Experimental Hypertension (New York, N.Y. : 1993)|May 15, 2012
Relationship of ambulatory blood pressure and the heart rate profile with renal function parameters in hypertensive patients with chronic kidney diseaseTomohiko Kanaoka, Kouichi Tamura, Masato Ohsawa, et al.
Biomed Research International|December 6, 2018
Early Enhanced Leucine-Rich <i>α</i>-2-Glycoprotein-1 Expression in Glomerular Endothelial Cells of Type 2 Diabetic Nephropathy Model MiceSona Haku, Hiromichi Wakui, Kengo Azushima, et al.
Cardiovascular Diabetology|January 8, 2021
Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysisTakayuki Yamada, Mako Wakabayashi, Abhinav Bhalla, et al.
Metabolism: Clinical and Experimental|October 19, 2023
Angiotensin II type 1 receptor-associated protein in immune cells: a possible key factor in the pathogenesis of visceral obesityShunichiro Tsukamoto, Toru Suzuki, Hiromichi Wakui, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|April 5, 2013
Therapeutic potential of low-density lipoprotein apheresis in the management of peripheral artery disease in patients with chronic kidney diseaseKouichi Tamura, Yuko Tsurumi-Ikeya, Hiromichi Wakui, et al.
Scientific Reports|August 20, 2021
Tissue-specific expression of the SARS-CoV-2 receptor, angiotensin-converting enzyme 2, in mouse models of chronic kidney diseaseShunichiro Tsukamoto, Hiromichi Wakui, Kengo Azushima, et al.
Pageof 11